Maarten J Bijlsma
Overview
Explore the profile of Maarten J Bijlsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katsimpokis D, Aarts M, Geleijnse G, Kunst P, Bijlsma M
J Clin Epidemiol
. 2025 Feb;
181:111711.
PMID: 39914790
Background And Objectives: With the introduction of immunotherapy with nonsmall cell lung cancer, prognosis of these patients has improved. However, socioeconomic differences in access to various immunotherapy treatments have been...
2.
van der Starre C, Bangma C, Bijlsma M, van den Bergh A, Kiemeney L, Kievit W, et al.
BMC Cancer
. 2025 Jan;
25(1):149.
PMID: 39871169
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily...
3.
Li X, Steenhuis D, Bijlsma M, de Vos S, Mubarik S, Bos J, et al.
Int J Gen Med
. 2024 Oct;
17:4947-4958.
PMID: 39478851
Purpose: Anti-hyperlipidemic drug treatments are effective in reducing the risk of cardiovascular disease. In a long-term retrospective inception cohort study, we aimed to assess the real-world comparative effectiveness of anti-hyperlipidemic...
4.
Li X, Bijlsma M, de Vos S, Bos J, Mubarik S, Schuiling-Veninga C, et al.
Front Pharmacol
. 2024 Jun;
15:1357567.
PMID: 38903996
Introduction: Antihypertensive drugs are used preventatively to lower the risk of cardiovascular disease events. Comparative effectiveness studies on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium...
5.
Gueltzow M, Lahtinen H, Bijlsma M, Myrskyla M, Martikainen P
Soc Sci Med
. 2024 May;
351:116992.
PMID: 38772210
Social relationships and genetic propensity are known to affect depression risk, but their joint effects are poorly understood. This study examined the association of a polygenic index for depression with...
6.
Verweij S, Ahmed W, Zhou G, Mavridis D, Nikolakopoulos S, Elferink A, et al.
Pharmacoepidemiol Drug Saf
. 2024 May;
33(5):e5810.
PMID: 38720409
Background: Randomized controlled trials are considered the gold standard in regulatory decision making, as observational studies are known to have important methodological limitations. However, real-world evidence may be helpful in...
7.
Gueltzow M, Groeniger J, Bijlsma M, Jansen P, Houweling T, van Lenthe F
Ann Epidemiol
. 2024 Apr;
94:19-26.
PMID: 38615897
Purpose: We investigated whether socioeconomic inequalities in young adolescents' mental health are partially due to the unequal distribution of childhood obesity across socioeconomic positions (SEP), i.e. differential exposure, or due...
8.
Alghamdi A, Bijlsma M, de Vos S, Schuiling-Veninga C, Bos J, Hak E
Pharmaceuticals (Basel)
. 2023 Dec;
16(12).
PMID: 38139820
Background: Alzheimer's disease (AD) is the most common cause of dementia, with a growing number of patients worldwide. The association between AD and treatment with drugs targeting the beta-adrenergic receptor...
9.
Eijkelboom A, de Munck L, Larsen M, Bijlsma M, Tjan-Heijnen V, van Gils C, et al.
Cancer Epidemiol
. 2023 Oct;
87:102481.
PMID: 37897970
Background: Comparing the impact of the COVID-19 pandemic on the incidence of newly diagnosed breast tumors and their tumor stage between the Netherlands and Norway will help us understand the...
10.
Zhou G, Verweij S, Bijlsma M, de Vos S, Oude Rengerink K, Pasmooij A, et al.
BMJ Open Respir Res
. 2023 Aug;
10(1).
PMID: 37640510
Objective: Current evidence on the effectiveness of SARS-CoV-2 prophylaxis is inconclusive. We aimed to systematically evaluate published studies on repurposed drugs for the prevention of laboratory-confirmed SARS-CoV-2 infection and/or COVID-19...